|
|
| | N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Basic information |
| | N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Chemical Properties |
| density | 1.303±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 0.2 mg/ml | | form | A crystalline solid | | pka | 13.05±0.46(Predicted) |
| | N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Usage And Synthesis |
| Biological Activity | TMP195 (TFMO 2) is a selective class IIa HDAC inhibitor with IC50 of 300 nM in cell-based assays. | | in vitro | TMP195 has low potency in recombinant class I and class IIb HDAC assays, and is able to completely inhibit class IIa HDAC activity without inhibiting other HDACs. In the supernatant of monocyte-derived macrophage differentiation medium, it prevented the accumulation of CCL2 protein; compared with the control group, it could significantly increase the level of CCL1 protein secreted by monocytes. | | target | | Target | Value | HDAC9
(Cell-free assay) | 15 nM(Ki) | HDAC7
(Cell-free assay) | 26 nM(Ki) | HDAC4
(Cell-free assay) | 59 nM(Ki) | HDAC5
(Cell-free assay) | 60 nM(Ki) |
|
| | N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Preparation Products And Raw materials |
|